Mitigating the burden of SARS-CoV-2 in at-risk populations with adapted COVID-19 vaccines
01 Jul 2024
About the event
A 1.5 hour webinar delivered by world-leading experts providing an overview of the following topics: Current burden posed by SARS-CoV-2 variants Mitigating the burden of COVID-19 through vaccine adaptation How do we sequester the need for seasonal COVID-19 vaccination to the community? The webinar includes an interactive Q&A session with the experts
At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized.
To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms.
